跳至主要内容
临床试验/ACTRN12624001061527
ACTRN12624001061527尚未招募4 期

Efficacy of Oral Lisdexamfetamine for the treatment of Acute Methamphetamine withdrawal symptoms (the OLAM trial): A randomised controlled trial

St Vincent's Hospital Sydney0 个研究点目标入组 184 人开始时间: 2024年9月3日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
184

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Aged 18 years and older
  • Presenting to drug treatment service seeking methamphetamine withdrawal treatment
  • Determined by an Addiction Medicine Specialist or Psychiatrist to have methamphetamine use disorder (DSM-5-TR criteria)
  • Reporting last use of methamphetamine within 72 hours of first dose of study drug
  • Point-of-care urine drug test positive for methamphetamine
  • Willing and able to provide written, informed consent

排除标准

  • Concurrent dependence on non-prescribed opioids or benzodiazepines, or alcohol or gamma-hydroxybutyrate (GHB) (based on DSM-5TR criteria)
  • Lactating, pregnant or of childbearing potential and not willing to avoid becoming pregnant during the study
  • Contraindications to lisdexamfetamine (per product label) other than drug dependence:
  • Acute severe mental/physical comorbidity that would interfere with study participation, as assessed by the site PI
  • Currently experiencing psychosis or suicidality
  • Exposure to lisdexamfetamine, dexamphetamine, modafinil or methylphenidate in the 4 weeks prior to screening

研究者

发起方
St Vincent's Hospital Sydney

相似试验